

## Biopharma Industry in India: Conclusion and Way Forward

16 September 2024 | Features

**A Report by Cactus Communications, written by Dr H. S. Sudhira, Director, Gubbi Labs**



The biopharma industry in India has been witnessing significant growth in recent years. With advancements in genetics, molecular biology, and Immunology, the industry is at a juncture of significantly impacting healthcare. Evolving around innovative frontiers such as biologics, biosimilars, vaccines, and emerging technologies like cell and gene therapy, the biopharma sector is positioned to become a global leader.

The Indian biopharma industry has a solid foundation owing to its extensive expertise in generic drugs. India has been a major player in the production and export of generic pharmaceuticals for many years. Its distinctive strengths reside in a vast pool of skilled scientific human resources, a robust network of research laboratories, a flourishing pharmaceutical industry, and a system that encourages innovation through various incentives. These underpinning strengths provide an encouraging basis for the advance of the biopharma industry.

A new wave of biologics is increasing India's potential in the biotech industry. Biologics, highly sophisticated large molecule drugs derived from living organisms, are revolutionizing the treatment approach for many severe diseases. These drugs, which include monoclonal antibodies and recombinant proteins, are known for their high efficacy and specificity in targeting diseases. With a growing demand for biologics globally, India has positioned itself as a preferred destination to produce these complex molecules due to its cost-effective manufacturing capabilities.

Biosimilars represent the next frontier in the growth of the Indian biopharma industry. India has become a prominent player in the biosimilars market due to its expertise in developing and manufacturing these products at competitive prices. The country's ability to produce high-quality biosimilars has enabled it to tap into the growing demand in both domestic and international markets. As the patents for original biologic medicines are expiring, the biosimilars market is expected to expand immensely.

Vaccines are another critical aspect that contribute robustly to the growth of India's biopharma industry. India, often referred to as the "pharmacy of the world," is one of the largest global vaccine suppliers. It is a global leader in vaccine manufacturing,

producing vaccines for diseases such as pneumonia, meningitis, rotavirus, yellow fever, and polio. Indian pharmaceutical companies play a vital role in ensuring affordable access to vaccines, particularly for low- and middle-income countries. The COVID-19 pandemic has underscored the critical functionality of the Indian vaccine industry. Indian companies like Serum Institute of India and Bharat Biotech have played integral roles in addressing the global vaccine demand, underscoring the industry's crucial role.

Furthermore, the Indian biopharma industry is also exploring emerging technologies like cell and gene therapy. These therapies have shown tremendous promise in treating various diseases, including cancer, genetic disorders, and autoimmune conditions. Currently in their nascent stages, these technologies are set to evolve rapidly, given their vast potential to revolutionize therapeutics. The country's focus on research and development, coupled with its cost-effective manufacturing capabilities, positions it well to capitalize on the growing demand for cell and gene therapies.

In addition, the advent of artificial intelligence (AI) and machine learning technologies are catalysing research and development processes in the biopharma industry by optimising drug design, shortening clinical trials, and improving diagnosis. These advanced technologies hold the promise of transforming the industry by allowing personalized medicine and improving disease management.

While it is evident that the potential for growth in India's biopharma industry is enormous, it is crucial to navigate the challenges that could slow this progress. These include regulatory challenges, high manufacturing costs, limited access to advanced technology, and talent shortage in specific areas. Nevertheless, with the government's support in creating favourable policies and making strategic investments, these challenges can be systematically addressed.

In conclusion, with the increasing confluence of biologics, biosimilars, vaccines, and emerging technologies like cell and gene therapy, the Indian biopharma industry is poised for a leap. The country's strength in science, research, and manufacturing, coupled with the ongoing evolution of advanced technologies, highlights India's potential to emerge as a global biopharma hub. However, integrating strategic policymaking, fostering research and innovation, and fortifying public-private partnerships are crucial to realise this potential completely and sustainably.



CACTUS<sup>®</sup>

#### **About Gubbi Labs**

Gubbi Labs is a private research collective that works on various domains ranging from sustainable ecosystems to liveable settlements. As part of its science communication initiative, it runs Research Matters, a multilingual science news portal.

#### **About Cactus Communications**

[Cactus Communications](#) is a science communication and technology company, accelerating scientific advancement by making science globally accessible.